TFRC and Alzheimer disease: Trontinemab (NCT04639050), a gantenerumab conjugated to a human transferrin receptor 1 (TfR1)-directed BrainshuttleTM module, demonstrates significantly greater brain uptake than gantenerumab, with brain distribution coefficients reported to be sevenfold to 33-fold higher across various brain regions [55];TfR1-mediated transcytosis is expected to alter the course of immunotherapy for AD.